

Product Data Sheet

Inhibitors • Screening Libraries •

Proteins

SEL120-34A monohydrochloride

HY-111388A	Br
2443816-41-7	Br
C ₁₅ H ₁₉ Br ₂ ClN ₄	
451	N
CDK	N=
Cell Cycle/DNA Damage	N-
4°C, sealed storage, away from moisture	
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)	HCI <u>NH</u>
	2443816-41-7 C ₁₅ H ₁₉ Br ₂ ClN ₄ 451 CDK Cell Cycle/DNA Damage 4°C, sealed storage, away from moisture

SOLVENT & SOLUBILITY

In Vitro	2 0, (H ₂ O : 50 mg/mL (110.86 mM; Need ultrasonic) DMSO : 16.67 mg/mL (36.96 mM; ultrasonic and warming and heat to 60°C)					
		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	2.2173 mL	11.0865 mL	22.1729 mL		
		5 mM	0.4435 mL	2.2173 mL	4.4346 mL		
		10 mM	0.2217 mL	1.1086 mL	2.2173 mL		
	Please refer to the so	Please refer to the solubility information to select the appropriate solvent.					
In Vivo		1. Add each solvent one by one: PBS Solubility: 14.29 mg/mL (31.69 mM); Clear solution; Need ultrasonic and warming and heat to 60°C					
		2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.67 mg/mL (3.70 mM); Clear solution					
		3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.67 mg/mL (3.70 mM); Clear solution					
		4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.67 mg/mL (3.70 mM); Clear solution					

BIOLOGICAL ACTIV	ИТҮ		
Description	and CDK19/CycC complexes w monohydrochloride weakly ir	vith IC ₅₀ s of 4.4 nM and 10.4 nM, i hibits CDK9 (calculated IC ₅₀ =107	lective CDK8 inhibitor, inhibits kinase activities of CDK8/CycC respectively, with a K _d of 3 nM for CDK8. SEL120-34A 70 nM), but shows no obvious activity against CDK1, 2, 4, 6, 5, 7. TAT1 S727 and STAT5 S726 ^[1] . Has anti-tumor activity ^[1] .
IC ₅₀ & Target	CDK8/CycC	CDK19/CycC	CDK9/cycT

	4.4 nM (IC ₅₀)	10.4 nM (IC ₅₀)	1070 nM (IC ₅₀)
In Vitro	and CDK19/CycC complexes w monohydrochloride weakly in [1]. SEL120-34A (1.6 nM-5 μM) inh MOLM13 AML cells ^[1] . SEL120-34A monohydrochlor expression and mitogen-indu	with IC_{50} s of 4.4 nM and 10.4 nM, r nhibits CDK9 (calculated IC_{50} =107 ibits the growth of STAT5 S726 pc ide inhibits phosphorylation of S ^T ced IER expression ^[1] .	lective CDK8 inhibitor, inhibits kinase activities of CDK8/CycC respectively, with a K _d of 3 nM for CDK8. SEL120-34A 70 nM), but shows no obvious activity against CDK1, 2, 4, 6, 5, 7 ositive KG-1 AML cells, but is not cytotoxic to S726 negative TAT1 S727 and STAT5 S726, decreases IRF9 and STAT1 mRNA nethods. They are for reference only.
In Vivo	manner in SCID mice after tre	eatment for 17 days ^[1] .	y day) inhibits growth of AML tumors in a dose-dependent nethods. They are for reference only.

CUSTOMER VALIDATION

- Cell. 2021 Apr 15;184(8):2167-2182.e22.
- Nat Commun. 2019 Oct 18;10(1):4741.
- Int J Mol Sci. 2022 Feb 24;23(5):2493.
- Friedrich-Alexander-Universität Erlangen-Nürnberg. 2023 Jun 23.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Rzymski T, et al. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains. Oncotarget. 2017 May 16;8(20):33779-33795.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA